Search Results

You are looking at 51 - 60 of 190 items for :

  • "Renal cell carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael Baine, Kathryn Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Payal Kapur, Christos Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon Manley, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey Sosman, Mary A. Dwyer, Lisa A. Gurski, and Angela Motter

Overview An estimated 76,080 Americans will be diagnosed with cancers of the kidney and renal pelvis and 13,780 will die of the disease in the United States in 2021. 1 Renal cell carcinoma (RCC) comprises approximately 3.8% of all new cancers

Full access

NCCN Evidence Blocks

Robert W. Carlson and Eric Jonasch

, Professor of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, and Vice Chair of the NCCN Kidney Cancer Panel, who described how this tool can be used in managing metastatic renal cell carcinoma (RCC). Evidence

Full access

Kidney Cancer

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, and Jue Wang

Hollingsworth JM Miller DC Dunn RL . Surgical management of low-stage renal cell carcinoma: technology does not supersede biology . Urology 2006 ; 67 : 1175 – 1180 . 10 Shuch B Lam JS Belldegrun AS . Open partial nephrectomy for the treatment or

Full access

Impact of the First Generation of Children’s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor

Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay A. Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez

kidney; FHWT, favorable histology Wilms tumor; LOH, combined loss of heterozygosity at chromosomes 1p and 16q; MRT, malignant rhabdoid tumor; RCC, renal cell carcinoma; WT, Wilms tumor. This article summarizes the key findings for WT and the

Full access

Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer

Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse

carcinoma; ILC, invasive lobular carcinoma; MAC, mucinous carcinoma; NOS, not otherwise specified; pNET, pancreatic neuroendocrine tumor; RCC, renal cell carcinoma; SCC, squamous cell carcinoma. This uncommon finding of a pathogenic PALB2 whole

Full access

We Have a New Treatment, But You Can't Afford It

Christopher E. Desch

, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor in patients with metastatic renal cell carcinoma . J Clin Oncol 2006 ; 24 : 16 – 24 . 2. Pfizer Oncology. Sutent

Full access

CLO19-050: Risk of Health- Related Quality of Life (HRQOL) Events in Patients With Advanced Solid Tumors Treated With Cabozantinib: A Combined Analysis of Four Phase 3 Randomized Controlled Trials

Sriman Swarup, Anita Sultan, Nusrat Jahan, Upama Sharma, Nimesh Adhikari, Yin M. Myat, Ye Aung, Myo H. Zaw, and Kyaw Z. Thein

,703 patients with medullary thyroid cancer, prostate cancer, renal cell carcinoma, and hepatocellular carcinoma were eligible. Studies comparing cabozantinib (C) vs everolimus, C vs placebo, C vs prednisone were included in the analysis. The relative risks of

Full access

Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model

Ágnes Benedict, Gábor Szabó, Kinga Marczell, Bridget Doherty, and Silas Martin

, multiple myeloma; NSCLC, non–small cell lung cancer; RCC, renal cell carcinoma. a Annual numbers are decreasing as newer indications become biomarker-specific. Scenario analyses assuming that all products have worse or better OS results, varied

Full access

Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival

Jake Johnson, Whitney Goldner, Duaa Abdallah, Fang Qiu, Apar Kishor Ganti, and Anupam Kotwal

Initiation When the groups were stratified by malignancy type, patients with melanoma had the highest frequency of hypophysitis (9/157), followed by patients with renal cell carcinoma (4/75) ( Table 1 ). Hypophysitis occurred most frequently after

Full access

Kidney Cancer

The UNMC Eppley Cancer Center at The Nebraska Medical Center

An estimated 38,890 Americans will be diagnosed with kidney cancer and 12,840 will die of this disease in the United States in 2006. Renal cell carcinoma (RCC) constitutes approximately 2% of all malignancies, with a median age at diagnosis of 65 years. Smoking and obesity are among the risk factors for RCC development, and tumor grade, local extent of the tumor, presence of regional nodal metastases, and evidence of metastatic disease at presentation are the most important prognostic determinants of 5-year survival. These guidelines discuss evaluation, staging, treatment, and management after treatment.

For the most recent version of the guidelines, please visit NCCN.org